Gevokizumab - Novartis
Alternative Names: S-78989; VPM 087; XMA-005.2; XMA-0052; XOMA-052Latest Information Update: 23 Mar 2025
At a glance
- Originator XOMA
- Developer IRIS; National Eye Institute; North Shore-Long Island Jewish Health System; Novartis; Servier; University of Zurich; XOMA
- Class Anti-inflammatories; Antiacnes; Antigouts; Antihyperglycaemics; Antineoplastics; Antirheumatics; Cardiovascular therapies; Eye disorder therapies; Immunotherapies; Monoclonal antibodies; Skin disorder therapies; Vascular disorder therapies
- Mechanism of Action Interleukin 1 beta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Colorectal cancer; Gastric cancer; Oesophageal cancer; Renal cell carcinoma
- Discontinued Acne vulgaris; Acute coronary syndromes; Diabetic nephropathies; Giant cell arteritis; Gout; Juvenile rheumatoid arthritis; Labyrinthitis; Myositis; Osteoarthritis; Pyoderma; Rheumatoid arthritis; Schnitzler syndrome; Scleritis; Type 1 diabetes mellitus; Type 2 diabetes mellitus; Uveitis
Most Recent Events
- 05 Feb 2025 Novartis Pharmaceuticals completes a phase I clinical trials in Oesophageal cancer (Combination therapy, Second-line therapy or greater, Metastatic disease) in Czech Republic, Japan, Singapore, the UK, US, Australia, Belgium, Canada, Chile, Germany, Israel, Italy, South Korea, Spain and Taiwan (IV) (NCT03798626)
- 23 Jul 2024 Discontinued - Phase-II for Acne vulgaris in USA (SC)
- 23 Jul 2024 Discontinued - Phase-II for Acute coronary syndromes in Canada, Netherlands, Finland (SC)